Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Oncology Pharma Inc.

Oncology Pharma Conducting Interviews and Presentations with Investors to Pursue Next Steps to Forward The Development Process of Nanoemulsion Drug Delivery System
From Oncology Pharma Inc.
Via AccessWire
Tickers ONPH
Oncology Pharma Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery System
From Oncology Pharma Inc.
Via AccessWire
Exposures Product Safety
Tickers ONPH
Oncology Pharma Announces: Initial Feasibility Study of the Nanoemulsion Drug Delivery System is Complete and Results Have Met the Threshold for Moving Forward To the Next Steps of Development
From Oncology Pharma Inc.
Via AccessWire
Tickers ONPH
Oncology Pharma Advances Progress on Multiple Fronts Including Advanced Attention to Connect2Trials' Commercial Development
From Oncology Pharma Inc.
Via AccessWire
Tickers ONPH
Oncology Pharma Completes Feasibility Phase of its Licensed Nanoemulsion Drug Delivery System to Treat Cancer
From Oncology Pharma Inc.
Via AccessWire
Tickers ONPH
Oncology Pharma Reports on Progress with Ribera Solutions
From Oncology Pharma Inc.
Via AccessWire
Tickers ONPH
Oncology Pharma Releases Further Feasibility Studies, Data and Capacities
From Oncology Pharma Inc.
Via AccessWire
Tickers ONPH
Oncology Pharma Expands on Feasibility Studies and Data
From Oncology Pharma Inc.
Via AccessWire
Tickers ONPH
Oncology Pharma, Inc. and Regen BioPharma, Inc. Announce Intent to Jointly Fast Track Development of Modified mRNA anti-Cancer Vaccine
From Oncology Pharma Inc.
Via AccessWire
Tickers ONPH RGBP RGBPP
Oncology Pharma Gives Update on Technology, Formulation and Data Creation
From Oncology Pharma Inc.
Via AccessWire
Tickers ONPH
Oncology Pharma's New Year Update
From Oncology Pharma Inc.
Via AccessWire
Tickers ONPH
Oncology Pharma Meeting Towards Future Developments
From Oncology Pharma Inc.
Via AccessWire
Tickers ONPH
Oncology Pharma Year End Review and Outlook
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Tickers ONPH
Oncology Pharma Research and Vision
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Tickers ONPH
Oncology Pharma Reveals Plans for Development of Lead Cancer Drug Candidate
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Tickers ONPH
Oncology Pharma, Inc. Gives Update on Ongoing Work and Progress
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers ONPH
Oncology Pharma, Inc. Has Engaged a PCAOB Audit Firm Looking Towards Moving the Company Towards a Senior Listing
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures Intellectual Property Legal Regulatory
Tickers ONPH
Oncology Pharma, Inc. Update on PCAOB Audit Selection Process and License Agreement
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers ONPH
Oncology Pharma, Inc. Has Received the Committed Funding to Perform All Necessary IND-Enabling Preclinical Work for Its First Lead Candidate, a Dactinomycin Nanoemulsion Drug Product
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Tickers ONPH
Oncology Pharma's Co-Development Agreement Pursues Strategic and Direct Objectives
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Tickers ONPH
Oncology Pharma, Inc. Executes Co-Development Agreement with NanoSmart Pharmaceuticals, Inc.
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Tickers ONPH
Oncology Pharma, Inc. To Move to Conducting Trials on Licensed IP
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers ONPH
Oncology Pharma, Inc. is Entering Into the Next Phase of its Growth and Expansion Phase
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Tickers ONPH
Oncology Pharma, Inc. Eyes Collaboration with Patent Opportunities Amongst Its Licensed Intellectual Properties
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers ONPH
Oncology Pharma and Ribera Solutions Release White Paper Regarding Patient Engagement and Retention Platform
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers ONPH
Oncology Pharma, Inc. Is Pursuing the Development of Its Small Molecule Drug for the Treatment of Colon Cancer
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers ONPH
Oncology Pharma, Inc. Has Submitted Its Initial Application to List the Company on the Capital Markets Tier of the NASDAQ Exchange
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers ONPH
Oncology Pharma Enters into License Agreement for Small Molecules Intellectual Property for the Treatment of Colon Cancer
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers ONPH
Oncology Pharma, Inc. Prepares Plan Toward Funding Development and Implementation of Ribera Solutions' Patient Engagement and Retention Platform
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers ONPH
Oncology Pharma, Inc. Addresses Pancreatic Cancer, the Need for an Effective Therapy and the Potential of mRNA Technology
From Oncology Pharma Inc.
Via AccessWire
Topics Death Intellectual Property
Exposures Death Intellectual Property
Tickers ONPH
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.